Funding Opportunity PAR-20-075 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Research Program Project Grant (P01) renewal (Type 2) applications. The proposed programs should address scientific areas relevant to the NIDDK mission including diabetes, selected endocrine and metabolic diseases, obesity, digestive diseases and nutrition, and kidney, urologic and hematologic diseases, as well as new approaches to prevent, treat and cure these diseases, including clinical research. A description of NIDDK scientific program areas can be found at https://www.niddk.nih.gov/about-niddk/research-areas.

Funding Opportunity PAR-20-076 from the NIH Guide for Grants and Contracts. Reissue of PAR-17-096. The Jointly Sponsored NIH Predoctoral Training Program in the Neurosciences (JSPTPN) is an institutional program that supports broad and fundamental research training in the neurosciences. In addition to a broad education in the neurosciences, a key component will be a curriculum that provides a strong foundation in experimental design, statistical methodology and quantitative reasoning. JSPTPN programs are intended to be 2 years in duration and students may only be appointed to this training grant during the first 2 years of their graduate research training. The primary objective is to prepare students to be outstanding scientists equipped to pursue careers in neuroscience.

Notice NOT-OD-20-044 from the NIH Guide for Grants and Contracts

Notice NOT-OD-20-043 from the NIH Guide for Grants and Contracts

Notice NOT-ES-20-005 from the NIH Guide for Grants and Contracts

Notice NOT-MH-20-004 from the NIH Guide for Grants and Contracts

Notice NOT-MH-20-005 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-015 from the NIH Guide for Grants and Contracts

Notice NOT-GM-20-008 from the NIH Guide for Grants and Contracts

Notice NOT-DA-20-026 from the NIH Guide for Grants and Contracts

Notice NOT-DA-20-025 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-19-028 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of novel and supportive technologies for the improvement of cell replacement interventions using novel methods, biomaterials and devices for type 1 diabetes (T1D) treatment.

Funding Opportunity PAR-20-074 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of this FOA is on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" r "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response in treatment, as well as markers for cancer control and prevention. Research applications may support the acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed for this FOA encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians, and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.

Notice NOT-MH-20-011 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-20-069 from the NIH Guide for Grants and Contracts. The purpose of this award is to support phased transition of outstanding graduate students from groups underrepresented in the biomedical, clinical, behavioral and social sciences research enterprise from graduate work to postdoctoral research positions in Dental, Oral, and Craniofacial (DOC) research. The first phase (F99) will support the final two years of graduate research training for individuals in PhD or dual degree clinician scientist programs. Following graduation and attainment of a postdoctoral research position, the second phase (K00) will provide support for up to three years of mentored postdoctoral research.

Funding Opportunity PAR-20-072 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs may address scientific areas relevant to the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function system development and function; and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immune-mediated, and allergic diseases. Each P01 application submitted to this FOA must include at least two related research projects that share a common central theme, focus, and/or overall objective.

Funding Opportunity PAR-20-070 from the NIH Guide for Grants and Contracts. This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities, and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.

Funding Opportunity PAR-20-071 from the NIH Guide for Grants and Contracts. This FOA invites applications that propose to support advanced-stage development and utilization of novel research infrastructure to advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Exploratory/Developmental Grants Phase II mechanism to provide support for expanded activities. Applicants are expected to have an existing research infrastructure developed, either through PA-12-064, or with other NIH or non-NIH support. Through this award, investigators will develop a mature and sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.

Funding Opportunity PAR-20-073 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is soliciting requests for access to dental practice-based research network (PBRN) resources for developmental/exploratory, pilot, and/or survey studies to be conducted in the to be conducted in the dental PBRN. Successful applicants will be given access to the NIDCR-funded dental PBRN infrastructure.

Funding Opportunity RFA-DK-19-023 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits U01 applications for the establishment of a clinical consortium, the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC), composed of one Data Coordinating Center (DCC) and up to 10 Clinical Centers (CC), to conduct studies on Type 1 diabetes mellitus (T1D) that occurs after or as a consequence of one or more episodes of acute pancreatitis. Applications for the Clinical Centers (CC) are submitted in response to a separate FOA: RFA-DK-19-022: Type 1 Diabetes in Acute Pancreatitis Consortium Clinical Centers (T1DAPC-CC) (U01). The applicant for the Data Coordinating Center (DCC) must have experience serving as the DCC for studies on complex, clinical conditions, like the occurrence of diabetes mellitus (DM) after or as a consequence of one or more episodes of acute pancreatitis. The Consortium will form multi-disciplinary teams composed of members from the CCs and the DCC to undertake a prospective longitudinal observational study of the occurrence of diabetes that occurs during an acute pancreatitis episode or subsequently, with an emphasis on type 1 diabetes (T1D). The study will be designed to gain insight into the incidence, clinical evolution, etiology, type and pathophysiology of the T1D and other forms of diabetes after acute pancreatitis.. The Consortia will also undertake studies on the identification of immune and genetic risk factors and biomarkers which predict the development of T1D in a racially, ethnically, and geographically diverse population of subjects who have recovered from one or more episodes of acute pancreatitis due to various identifiable etiologies. The DCC will provide overall project coordination, administration, quality control, data management and biostatistical support.